Abstract: Disclosed is a technique for switching from a master node to a secondary node in a communication system. A method of a first communication node may comprise: adding the first communication node as a primary secondary cell (PSCell) to a second communication node through dual connectivity (DC); generating a first user plane path for smart dynamic switching (SDS) and a first instance for supporting the first user plane path according to a request from the second communication node; transmitting information on the first user plane path and the first instance to a terminal; receiving user data based on the first user plane path from the terminal as the first instance; and transmitting the user data to a core network using the first user plane path.

Abstract: The present disclosure relates to a novel cell-penetrating multifunctional peptide, a composition including the same.

Abstract: Disclosed herein are a system and method for recommending repeat-purchase products using modified self-similarity. The system is operated by a computer in an environment in which user equipment (UE), a database, and a web server are connected over a network.

Abstract: The present invention relates to a composition for bone regeneration comprising METTL7A-overexpressing stem cells, a method for preparing the same, and a cell therapy product comprising the same. According to the invention, it is possible to enhance the osteogenic differentiation ability and viability of stem cells compared to conventional stem cell therapy products for bone regeneration.

Abstract: The present invention relates to an anticancer drug composition comprising, as an active ingredient, TLR5 agonist derived from flagellin. The TLR5 agonist derived from flagellin of the present invention can exhibit an anticancer or anticancer adjuvant effect alone or concurrently with an immune checkpoint blockade, and thus, can be developed as a cancer cell growth inhibitory active ingredient.

Abstract: The present invention relates to a method for inducing and proliferating target virus antigen-specific dual activated T cells, and can produce target virus antigen-specific dual activated T cells by treating monocytes, which are isolated from peripheral blood, with a cytokine and a virus antigen peptide mixture and culturing the same.

Abstract: The present disclosure relates to a safe driving support system based on a mobile Internet of Things (IoT) agent, and a processing method thereof. The safe driving support system based on a mobile IoT agent may provide an accident response service for preventing a traffic accident in advance by obtaining GNSS-based position information of each of vehicles, collecting various information on a driver's status and a vehicle driving status of the vehicle that is being driven in real time to construct big data, and analyzing and repeatedly learning the collected information. According to the present disclosure, it is possible to provide the ground for providing various services capable of decreasing traffic accidents by obtaining driving information of a short cycle using a GNSS platform and analyzing the driving information to apply the driving information to traffic safety and accident prevention activities.

Abstract: The present disclosure relates to a composition for preventing or treating graft-versus-host disease (GVHD) containing a TLR5 agonist derived from flagellin as an active ingredient. The TLR5 agonist derived from flagellin according to the present disclosure exhibits an excellent therapeutic effect against GVHD, and thus may be developed as an active ingredient for a composition for the treatment, prevention or alleviation of GVHD.

Abstract: Disclosed herein are a system and method for recommending repeat-purchase products using modified self-similarity. The system is operated by a computer in an environment in which user equipment (UE), a database, and a web server are connected over a network.

Abstract: The present invention relates to a non-viral minicircle vector expressing a SOX gene, a stem cell into which the vector is introduced, a pharmaceutical composition for preventing or treating a cartilage disease, including the stem cell, and a method for constructing the vector. The transformation of mesenchymal stem cells with MC/SOX-Trio or MC/SOX-Duo, which is a non-viral minicircle vector according to the present invention, can completely exclude the necessity of expensive growth factors that have been indispensably used in inducing the differentiation of mesenchymal stem cells into chondrocytes. Accordingly, the mesenchymal stem cells transformed therewith, when implanted in vivo, can differentiate into chondrocytes by themselves, and thus have an advantage capable of simplifying the existing complicated steps of culturing cells to induce differentiation and then transplanting the cells.

Abstract: The present invention relates to a polymeric micelle including a kartogenin derivative, a hyaluronic acid hydrogel including the same, a method for producing the same, and a use thereof, and the polymeric micelle and the hyaluronic acid derivative hydrogel including the polymeric micelle slowly release kartogenin, and thus may be usefully used for the purpose of preventing or treating various cartilage disorder-related diseases such as degenerative arthritis because an effect of regenerating chondrocytes while protecting chondrocytes is excellent.

Abstract: The present invention relates to a non-viral minicircle vector expressing a SOX gene, a stem cell into which the vector is introduced, a pharmaceutical composition for preventing or treating a cartilage disease, including the stem cell, and a method for constructing the vector. The transformation of mesenchymal stem cells with MC/SOX-Trio or MC/SOX-Duo, which is a non-viral minicircle vector according to the present invention, can completely exclude the necessity of expensive growth factors that have been indispensably used in inducing the differentiation of mesenchymal stem cells into chondrocytes. Accordingly, the mesenchymal stem cells transformed therewith, when implanted in vivo, can differentiate into chondrocytes by themselves, and thus have an advantage capable of simplifying the existing complicated steps of culturing cells to induce differentiation and then transplanting the cells.

Abstract: The present invention relates to a composition for preventing or treating mucositis comprising NecroX. It was found that NecroX has effects of reducing the disease mortality rate by means of radiotherapy or chemotherapy in a NecroX administration group, protecting intestinal functions, inhibiting destruction of intestinal mucous membrane, and proliferating the cells present in intestines. NecroX may be used for a pharmaceutical composition for preventing or treating mucositis, an anti-cancer adjuvant, or a food composition.

Abstract: The objective of the present invention is to effectively improve an image lag phenomenon of a direct conversion detector. The present invention provides an X-ray detector comprising: a lower electrode, formed on a substrate, to which a first driving voltage V1 is applied; an auxiliary electrode, around the lower electrode, to which a third driving voltage V3 is applied; a photoconductive layer formed on the lower electrode and the auxiliary electrode; and an upper electrode, formed on the photoconductive layer, to which a second driving voltage V2 is applied, wherein the third driving voltage V3, right after the radiation of the X-rays is off, is a reverse bias voltage.

Abstract: The present invention relates to a method for inducing and proliferating target virus antigen-specific dual activated T cells, and can produce target virus antigen-specific dual activated T cells by treating monocytes, which are isolated from peripheral blood, with a cytokine and a virus antigen peptide mixture and culturing the same.

Abstract: The present invention relates to kartogenin-conjugated chitosan particles with an improved sustained release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and retention time in the joints were confirmed by using kartogenin-chitosan microparticles or kartogenin-chitosan nanoparticles of the present invention, and thus targeted treatment, in the prevention or treatment of bone diseases, is enabled through a more fundamental approach.

Abstract: The present invention relates to a Krueppel-like factor 10 (KLF10) gene expression inhibitor promoting cartilage differentiation, and more specifically, to: a composition for promoting chondrocyte differentiation or treating cartilage diseases, containing a KLF10 gene expression inhibitor promoting cartilage differentiation and inhibiting the hypertrophy and dedifferentiation of chondrocytes; a cell therapeutic agent containing the composition; a method for promoting cartilage differentiation in bone marrow stem cells, comprising a step of expressing the composition in bone marrow stem cells; and a method for screening a chondrocyte differentiation promoter or a chondrocyte therapeutic agent.

Abstract: The present invention relates to new medical use of (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholine-4-yl)methyl-1H-indol-7-yl]amine, and more particularly, to a pharmaceutical composition containing the compound as an active ingredient, which is used for inhibiting an immune response, and/or for inducing differentiation into regulator T cells from undifferentiated T cells and/or promoting proliferation of regulator T cells.

Abstract: The present invention relates to a composition for preventing or treating mucositis comprising NecroX. It was found that NecroX has effects of reducing the disease mortality rate by means of radiotherapy or chemotherapy in a NecroX administration group, protecting intestinal functions, inhibiting destruction of intestinal mucous membrane, and proliferating the cells present in intestines. NecroX may be used for a pharmaceutical composition for preventing or treating mucositis, an anti-cancer adjuvant, or a food composition.

Abstract: The present invention relates to kartogenin-conjugated chitosan particles with an improved sustained release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and retention time in the joints were confirmed by using kartogenin-chitosan microparticles or kartogenin-chitosan nanoparticles of the present invention, and thus targeted treatment, in the prevention or treatment of bone diseases, is enabled through a more fundamental approach.